国庆请假休29天

山东：让城乡居民“敢消费”“能消费”“愿消费”_我的网站

父母爱情

一 | 消费是经济增长的重要推动力。 (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed. China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval. A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country. Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category. This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading. At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly. To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong. The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions. In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total. (By Tang Yuxian) 。

二 | 1月8日，在山东省人民政府新闻办公室举行“干字当头勇挑大梁”主题系列新闻发布会上，山东省财政厅二级巡视员单卫国表示，2024年，山东财政部门坚决贯彻中央和省委省政府关于扩内需促消费的决策部署，加大资金投入力度，完善财政政策措施，努力推动消费持续向好。

三 | 多渠道增加个人收入，让城乡居民“敢消费”。按照国家部署，省级统筹安排资金524亿元，将居民养老保险基础养老金最低标准提高到每人每月188元，将居民医保财政补助标准提高到670元，并连续提高退休人员基本养老金，进一步完善社会保障体系，让老百姓放心消费。筹集资金52.4亿元，支持市县落实城乡公益性岗位补贴、职业培训补贴等就业扶持政策，着力稳定和扩大就业，千方百计增加老百姓收入。

四 | 支持开展消费品以旧换新，让城乡居民“能消费”。2024年全省筹集落实资金143.21亿元，集中支持汽车、家电等8个领域消费品以旧换新工作，有力带动了消费回升。支持优化消费环境，让城乡居民“愿消费”。支持济南、青岛成功入选全国首批现代商贸流通体系试点城市，加快建设城乡融合、高效顺畅的现代商贸流通体系。省级统筹安排资金，支持开展“好品山东商行天下”、山东品牌中华行等一系列促消费活动，加快完善县域商业体系，打造“智慧商圈”，为老百姓营造更加便捷的消费环境。（大众新闻记者王欣怡策划孙源泽）。